Analysts upbeat on Ryman
Ryman Healthcare is still being tipped as a good investment, despite its share price bouncing off record highs to what analysts are now calling "fair value".
The retirement operator's shares rose nearly 68 per cent last year to peak this month at $4.80.
The stock has since slipped to $4.53 as investors book profits on what appears to be the belief that sentiment has outstripped the firm's fundamentals.
However, equity analysts remain upbeat about Ryman's prospects, and see earnings bolstered by momentum in the housing market and cashflow from growth in existing villages. Of six analysts polled by Reuters, three rate the stock as "buy", two as "hold", and one as "sell".
The head of private wealth research at Craigs Investment Partners, Mark Lister, said he viewed the stock as fully priced with a price-earnings multiple of 17, but still viewed Ryman as an "outstanding company" set to deliver earnings and dividend growth in the year ahead.
That was partly due to its building spree in 2007 and 2008, with those completed villages generating maximum cashflow from services and the resale of units on a depreciated basis.
A private investor in the New Zealand retirement sector said the cashflow, in conjunction with construction of new villages, was providing "serious inertia" to Ryman.
The firm, along with other village operators, was also benefiting from the recovery of the housing market, Forsyth Barr analyst Jeremy Simpson said. Fairfax NZ
Taranaki Daily News